PT  - JOURNAL ARTICLE
AU  - Han, Yang
AU  - Jia, Zhilong
AU  - Shi, Jinlong
AU  - Wang, Weidong
AU  - He, Kunlun
TI  - The active lung microbiota landscape of COVID-19 patients
AID  - 10.1101/2020.08.20.20144014
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.20.20144014
4099  - http://medrxiv.org/content/early/2020/08/23/2020.08.20.20144014.short
4100  - http://medrxiv.org/content/early/2020/08/23/2020.08.20.20144014.full
AB  - With the outbreak of COVID-19 causing by SARS-CoV-2, the interaction between the host and SARS-CoV-2 was widely studied. However, it is unclear whether and how SARS-CoV-2 infection affects lung microflora, which contributes to COVID-19 complications. Here, we analyzed the metatranscriptomic data of bronchoalveolar lavage fluid (BALF) of 19 COVID-19 patients and 23 healthy controls from 6 independent projects and detailed the active microbiota landscape in both healthy individuals and COVID-19 patients. The infection of SARS-CoV-2 could deeply change the lung microbiota, evidenced by the α-diversity, β-diversity and species composition analysis based on bacterial microbiota and virome. Pathogens (such as Klebsiella oxytoca causing pneumonia as well), immunomodulatory probiotics (such as Lactic Acid Bacteria and Faecalibacterium prausnitzii, a butyrate producer) and Tobacco mosaic virus (TMV) were enriched in the COVID-19 group, suggesting a severe microbiota dysbiosis. The significant correlation between Rothia mucilaginosa, TMV and SARS-CoV-2 revealed drastic inflammatory battles between the host, SARS-CoV-2 and other microbes in the lungs. Notably, TMV only existed in the COVID-19 group, while Human respirovirus 3 only existed in the healthy group. Our study provides insight into the active microbiota in the lungs of COVID-19 patients and will contribute to the understanding of the infection mechanism of SARS-CoV-2 and the treatment of the disease and complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China [grant numbers 31701155]; National Key Research and Development Program of China [grant number 2017YFC0908403].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw datasets analyzed for this study were downloaded from Sequence Read Archive, EMBL-EBI ArrayExpress and National Genomics Data Center, China with project IDs, PRJCA002202, PRJNA601736, PRJCA002326, PRJNA605983, PRJNA615032 and PRJNA434133.